Non Alcoholic Fatty Liver Disease in Rheumatoid Arthritis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00394238|
Recruitment Status : Unknown
Verified July 2006 by Shaare Zedek Medical Center.
Recruitment status was: Not yet recruiting
First Posted : October 31, 2006
Last Update Posted : October 31, 2006
Rheumatoid arthritis is a chronic inflammatory systemic disease. It has a worldwide distribution and can affect all age group. The peak incidence is between fourth and sixth decade. It is more prevalent in women, and it’s prevalence in the general population in North America is between 0.2-1.5%. The etiology of RA is unknown, although clusters of the disease in families and high concordance in mono-zydotic twins support genetic predisposition. The prevalence of fatty liver disease in patients with rheumatoid arthritis is currently unknown. We wish to study the link between the two conditions by performing a son graphic imaging of the liver in a cohort of RA patients. If indeed a high prevalence of NAFLD will be found in the RA patients, further support will be landed for the link between inflammation and fatty liver disease. These findings may also have implications regarding the management and follow up of RA patients.
The validity of sonographic imaging for detection of fatty liver diseases is currently accepted: On ultrasonographic, fatty infiltration of the liver produces a diffuse increase in echogenicity as compared with that of the kidneys. Ultrasonography has a sensitivity of 89% and a specificity of 93% in detecting steatosis and sensitivity and specificity of 77% and 89% respectively in detecting increase fibrosis.
In view of all the above data, we expected to find higher prevalence of fatty liver in the patients with higher inflammation markers compare with patients with lower markers.
|Condition or disease||Intervention/treatment|
|Arthritis, Rheumatoid||Procedure: Ultrasonographic imaging|
|Study Type :||Observational|
|Enrollment :||50 participants|
|Observational Model:||Defined Population|
|Study Start Date :||November 2006|
|Study Completion Date :||October 2008|
U.S. FDA Resources
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00394238
|Contact: Ornit Cohen, Mscemail@example.com|
|Rheumatoid Clinic||Not yet recruiting|
|Contact: Michal Mates, MD 0544727635 Mates@013.net|
|Contact: Ornit Cohen, MSc 0507867234 firstname.lastname@example.org|
|Principal Investigator: Michal Mates, MD|
|Principal Investigator:||Michal Mates, MD||Shaare Zedek Medical Center Jerusalem|